Xmetix

Xmetix is an Israeli defensetech startup founded in 2024 that has engineered a fundamentally different approach to tourniquet application in high-stress environments. The company's core product, the TAK710, is an automatic tourniquet that eliminates the need for trained application in field conditions. The device addresses one of the most critical gaps in battlefield medicine: the time-critical control of life-threatening extremity hemorrhage when medical personnel are unavailable, untrained responders are mobilized, or chaos in mass casualty scenarios prevents proper triage sequencing. The product's automation was conceived by CEO Edan Razinovsky in response to the mass casualty incidents of October 7, 2023, which demonstrated the extreme scalability demands of emergency response systems and the central role that rapid hemorrhage control plays in casualty survival.

The TAK710 represents a meaningful advancement in tactical medical technology through its elimination of operator error and training prerequisites—critical factors in mass casualty triage where deployed responders may be civilians, law enforcement, or military personnel with limited medical training. Current market-leading products like the CAT tourniquet and SOFTT-W require skilled application, multiple steps, and training to be effective, creating bottlenecks in scenarios where dozens or hundreds of people are injured simultaneously. Xmetix's automatic mechanism substantially reduces these dependencies, enabling deployment at scale by diverse responder types. The company's technology focus extends to miniaturization and combat ergonomics, ensuring the device is compatible with tactical load-outs and can be deployed from standard first-aid kits or worn on body armor.

Commercial viability and strategic positioning have been strengthened by early traction in the defense sector. Xmetix showcased the TAK710 at the Defense Tech Expo 2026 in Tel Aviv and has attracted formal interest from international government procurement agencies, including Australia's military and emergency services. This early-stage validation from defense procurers signals credible market demand and provides a pathway to scaled production and certification. The Israeli setting is advantageous for initial product development and government relationships, as Israel's defense ministry and medical corps can serve as reference customers, and Israeli startups benefit from established procurement pathways and national-security focus that prioritizes innovative medical equipment.

The dual-use potential is exceptionally strong. Militaries worldwide face increasing casualty management challenges; the U.S. military, NATO allies, and Indo-Pacific partners including Australia are all investing in casualty reduction initiatives. Simultaneously, civilian emergency responders—fire departments, law enforcement, urban EMS—are integrating tourniquet deployment into first-responder protocols, especially in response to active-threat scenarios. The TAK710's ease of use makes it attractive across both domains, differentiating it from incumbents and positioning it as a true cross-sector product that serves defense procurement budgets, civilian emergency management, and public health resilience goals.